3-(4-fluorophenyl)-4-(4-methoxyphenyl)-5-methylisoxazole | 1402042-27-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-(4-fluorophenyl)-4-(4-methoxyphenyl)-5-methylisoxazole
• 英文别名: 3-(4-Fluorophenyl)-4-(4-methoxyphenyl)-5-methyl-1,2-oxazole；3-(4-fluorophenyl)-4-(4-methoxyphenyl)-5-methyl-1,2-oxazole
• CAS: 1402042-27-6
• 化学式: C₁₇H₁₄FNO₂
• 分子量: 283.302
• InChiKey: UMTICMVTSDCINS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  二氧化碳 、 3-(4-fluorophenyl)-4-(4-methoxyphenyl)-5-methylisoxazole 在 正丁基锂 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 以50%的产率得到2-[3-(4-fluorophenyl)-4-(4-methoxyphenyl)isoxazol-5-yl]acetic acid
  参考文献：
  名称：

  Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability

  摘要：

  A set of novel diarylisoxazoles has been projected using mofezolac (1) as a lead compound to investigate structure-inhibitory activity relationships of new compounds and the cyclooxygenases (COXs) catalytic activity. Mofezolac was chosen because is the most potent and selective reversible COX-1 inhibitor [COX-1 IC50 = 0.0079 mu M and COX-2 IC50 > 50 mu M, with a selectivity index (SI) in favor of COX-1 higher than 6300]. Seventeen new compounds were synthesized in fair to good yields and evaluated for their COXs inhibitory activity and selectivity. Sls ranged between 1 and higher than 11903,4-Bis(4-methoxyphenyl)-5-vinylisoxazole (22) has the highest SI with COX-1 IC50 = 0.042 mu M and COX-2 IC50 > 50 mu M. 1 and 22 were superior to aspirin in inhibiting platelet aggregation (IC50 = 0.45, 0.63 and 1.11 mu M, respectively) in human platelet rich plasma (hPRP) assay. They did not induce blood coagulation and hemolysis, and are neither genotoxic nor mutagen. 1 and 22 slightly increase bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor bortezomib, a drug clinically used to treat plasma cell neoplasms including MM. In addition, structure-based binding mode of 1 and 22, through Fingerprints for Ligands and Proteins (FLAG) calculation, allowed to explain the one order of magnitude difference between COX-1 IC50 values of the two compounds. Specifically, the higher inhibitory potency seems due to the formation of a H-bond between COX-1 S530 and the carboxyl, present in 1 and absent in 22. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.12.029
• 作为产物：
  描述：

  对甲氧基苯基丙酮 、 p-fluorobenzonitrile oxide 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以50%的产率得到3-(4-fluorophenyl)-4-(4-methoxyphenyl)-5-methylisoxazole
  参考文献：
  名称：

  Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability

  摘要：

  A set of novel diarylisoxazoles has been projected using mofezolac (1) as a lead compound to investigate structure-inhibitory activity relationships of new compounds and the cyclooxygenases (COXs) catalytic activity. Mofezolac was chosen because is the most potent and selective reversible COX-1 inhibitor [COX-1 IC50 = 0.0079 mu M and COX-2 IC50 > 50 mu M, with a selectivity index (SI) in favor of COX-1 higher than 6300]. Seventeen new compounds were synthesized in fair to good yields and evaluated for their COXs inhibitory activity and selectivity. Sls ranged between 1 and higher than 11903,4-Bis(4-methoxyphenyl)-5-vinylisoxazole (22) has the highest SI with COX-1 IC50 = 0.042 mu M and COX-2 IC50 > 50 mu M. 1 and 22 were superior to aspirin in inhibiting platelet aggregation (IC50 = 0.45, 0.63 and 1.11 mu M, respectively) in human platelet rich plasma (hPRP) assay. They did not induce blood coagulation and hemolysis, and are neither genotoxic nor mutagen. 1 and 22 slightly increase bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor bortezomib, a drug clinically used to treat plasma cell neoplasms including MM. In addition, structure-based binding mode of 1 and 22, through Fingerprints for Ligands and Proteins (FLAG) calculation, allowed to explain the one order of magnitude difference between COX-1 IC50 values of the two compounds. Specifically, the higher inhibitory potency seems due to the formation of a H-bond between COX-1 S530 and the carboxyl, present in 1 and absent in 22. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.12.029

文献信息

• Monodentate Palladium Complexes Bearing Abnormal and Normal Carbene Ligands with a Formally Identical Steric Environment
  作者：Chun-Hung Ke、Bing-Chiuan Kuo、Debkumar Nandi、Hon Man Lee

  DOI：10.1021/om4004219

  日期：2013.9.9

  environment around the metal center. The corresponding ligand precursors were prepared via the key steps based on Pd-catalyzed direct C–H arylation between imidazo[1,2-a]pyridine and aryl bromides and Cu-catalyzed C–N coupling reactions between benzoimidazole and aryl bromides. The new complexes were characterized by 1D and 2D NMR spectroscopy, X-ray crystallography, and elemental analysis. The isomeric

  我们报告了一系列具有单齿异常和正常卡宾配体的新型异构Pd（II）配合物，在金属中心周围具有形式上完全相同的空间环境。相应的配体前体是通过基于咪唑并[1,2- a]之间的Pd催化的直接CH芳基化的关键步骤制备的]吡啶和芳基溴化物以及铜催化的苯并咪唑与芳基溴化物之间的C–N偶联反应。通过1D和2D NMR光谱，X射线晶体学和元素分析对新配合物进行了表征。配体的同分异构体对在其空间性质之间显示出较小的差异，这可以通过计算其掩埋体积来检查。发现异常卡宾Pd（II）配合物在催化Mizoroki–Heck偶联，直接C–H芳基化和脱羧偶联反应方面更有效，这显然可以归因于异常卡宾配体的更强的电子捐赠作用。
• Pd(0)-Catalyzed Decarboxylative Coupling and Tandem C–H Arylation/Decarboxylation for the Synthesis of Heteroaromatic Biaryls
  作者：Debkumar Nandi、Yang-Ming Jhou、Jhen-Yi Lee、Bing-Chiuan Kuo、Chien-Yu Liu、Pei-Wen Huang、Hon Man Lee

  DOI：10.1021/jo3015837

  日期：2012.10.19

  An effective Pd(0) carbene complex was successfully employed in the decarboxylative coupling of the heteroaromatic carboxylic acids (imidazo[1,2-a]pyridine and isoxazole) with aryl halides. For carboxyindoles, either decarboxylative coupling or tandem C-H arylation and decarboxylation occurred, leading to the formation of C2-monoarylated indoles.